01875.HK
BioDlink International Company Limited
HKSE · Healthcare · Biotechnology · CN
HKD 3.80
−0.39%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.6B | 747.6M | 1.1B | 780.6M | 442.2M |
| Cost of Revenue | 721.6M | 358.7M | 315.9M | 206.6M | 71.6M |
| Gross Profit | 846.4M | 389.0M | 782.4M | 574.0M | 370.6M |
| Operating Expenses | |||||
| R&D Expense | 145.6M | 85.7M | 79.3M | 103.9M | 151.2M |
| SG&A Expense | 860.5M | 401.6M | 688.1M | 509.3M | 266.5M |
| General & Admin Expense | 126.8M | 77.5M | 81.4M | 68.3M | 62.6M |
| Selling & Marketing Expense | 654.3M | 324.1M | 606.7M | 441.0M | 204.0M |
| Other Expenses | (23.1M) | (7.6M) | (26.2M) | (6.2M) | (8.3M) |
| Total Operating Expenses | 983.0M | 479.7M | 741.2M | 607.0M | 409.4M |
| Cost and Expenses | 1.7B | 838.3M | 1.1B | 813.7M | 481.0M |
| Operating Income (EBIT) | (136.6M) | (90.7M) | 41.3M | (33.1M) | (39.1M) |
| Non-Operating | |||||
| Interest Income | 4.3M | 2.2M | 3.4M | 3.0M | 2.3M |
| Interest Expense | 21.0M | 11.9M | 9.9M | 5.2M | 6.6M |
| Net Interest Income | (19.3M) | (9.7M) | (6.5M) | (2.2M) | (4.3M) |
| Other Non-Op Income/Expense | (18.3M) | (9.7M) | (6.5M) | (4.7M) | (11.0M) |
| Non-Operating Income (excl Interest) | (15.4M) | (10.2M) | (4.9M) | (479.0K) | 4.4M |
| EBT (Pre-Tax Income) | (154.9M) | (100.4M) | 34.8M | (37.8M) | (50.0M) |
| Income Tax Expense | — | — | — | 1.0K | — |
| Bottom Line | |||||
| Net Income | (154.9M) | (100.4M) | 34.8M | (37.8M) | (49.9M) |
| Earnings from Cont. Ops | (154.9M) | (100.4M) | 34.8M | (37.8M) | (50.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (154.9M) | (100.4M) | 34.8M | (37.8M) | (49.9M) |
| Per Share | |||||
| Basic EPS | (HK$0.21) | (HK$0.14) | HK$0.05 | (HK$0.05) | (HK$0.08) |
| Diluted EPS | (HK$0.21) | (HK$0.14) | HK$0.05 | (HK$0.05) | (HK$0.08) |
| Revenue Per Share | HK$2.16 | HK$1.03 | HK$1.51 | HK$1.08 | HK$0.69 |
| Shares | |||||
| Basic Shares Outstanding | 725.2M | 725.2M | 725.2M | 725.2M | 639.3M |
| Diluted Shares Outstanding | 725.2M | 725.2M | 725.2M | 725.2M | 639.3M |
| Profitability Metrics | |||||
| EBITDA | 3.0M | (6.4M) | 85.0M | 10.4M | (5.4M) |
| D&A | 124.2M | 74.0M | 38.8M | 43.0M | 38.0M |
| EBIT | (121.2M) | (80.5M) | 46.2M | (32.6M) | (43.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026